Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment

Hajer Ziouziou; Claudia Andrieu; Erik Laurini; Sara Karaki; Maurizio Fermeglia; Ridha Oueslati; David Taieb; Michel Camplo; Olivier Siri; Sabrina Pricl; Maria Katsogiannou; Palma Rocchi

doi:10.18632/oncotarget.25683

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment

PDF | How to cite

Oncotarget. 2018; 9:28797-28797. https://doi.org/10.18632/oncotarget.25683

Metrics: PDF 1439 views | ?

Hajer Ziouziou^1,2,3,4,7, Claudia Andrieu^1,2,3,4, Erik Laurini^5,6, Sara Karaki^1,2,3,4, Maurizio Fermeglia^5,6, Ridha Oueslati⁷, David Taieb^1,2,3,4, Michel Camplo⁶, Olivier Siri⁸, Sabrina Pricl^5,6, Maria Katsogiannou^1,2,3,4 and Palma Rocchi^1,2,3,4

¹Inserm, UMR1068, CRCM, Marseille, France
²Institut Paoli-Calmettes, Marseille, France
³Aix-Marseille Université, Marseille, France
⁴CNRS, UMR7258, CRCM, Marseille, France
⁵Molecular Simulation Engineering (MOSE) Laboratory, DEA, University of Trieste, Trieste, Italy
⁶National Interuniversity Consortium for Material Science and Technology (INSTM), Research Unit MOSE-DEA, University of Trieste, Trieste, Italy
⁷Unit of Immunology Microbiology Environmental and Carcinogenesis (IMEC), Science Faculty of Bizerte, University of Carthage, Bizerte, Tunisia
⁸Aix-Marseille Université, CNRS, Centre Interdisciplinaire de Nanoscience de Marseille, UMR 7325, Marseille, France

Published: June 19, 2018

This article has been corrected: The proper listing of author names is given below:

Original article: 2017; 8:77317-77329. DOI: https://doi.org/10.18632/oncotarget.20469.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25683

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment